Pliant Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Pliant Therapeutics, Inc. (PLRX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-210.30-161.34-123.32-97.26-41.53
Depreciation & Amortization2.13-0.801.821.541.30
Stock Based Compensation37.6344.4822.6010.443.90
Change in Working Capital9.094.004.226.92-1.21
Change in Accounts Receivable0.001.980.027.28-2.23
Change in Accounts Payable1.432.97-1.350.890.92
Change in Other Working Capital3.45-3.705.55-1.26-0.15
Other Operating Activities3.4541.741.861.674.16
Net Cash from Operating Activities-155.50-116.36-94.63-75.44-37.27
Investing Activities
Capital Expenditures-3.850.92-1.76-1.951.53
Purchases of Investments-211.29-126.09-148.4475.65-209.33
Sales/Maturities of Investments355.47-126.09-148.44295.54-209.33
Net Cash from Investing Activities140.34-127.01-150.2073.70-210.87
Financing Activities
Debt Repayment19.910.00-0.150.000.00
Common Stock Issued3.21270.25217.562.98160.75
Other Financing Activities0.004.15-0.56-0.460.00
Net Cash from Financing Activities23.12274.41226.852.53213.21
Summary
Net Change in Cash7.9531.03-17.980.78-34.93
Cash at Beginning of Period64.7233.6851.6750.8885.81
Cash at End of Period72.6764.7233.6851.6750.88
Free Cash Flow-159.35-117.28-96.39-77.40-38.80
Supplemental Disclosures
Interest Paid2.621.150.620.000.00